Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
A study found that young women in the United States had a higher incidence of lung cancer that could not be explained by known risk factors, such as smoking.
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.
